AHNAK and cancer: Some of the splicing targets, including LDHA, TNFSF13 and ARHGAP4 for intron retention, MARCH7, PCBP2 and LRCH3 for exon skipping and VGLL4, AHNAK and NFE2L1 that are subjected to alternative first exon usage may potentially contribute to cancer cell hypoxic adaptation by altering cellular metabolism, transcriptional regulation, actin cytoskeleton organization and promoting cancer cell proliferation, migration and invasion.